Novel agents in development for advanced non-small cell lung cancer.
about
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialNovel targeted agents for the treatment of lung cancer in ChinaCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsLipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinomaThe relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFRConstruction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.Pharmacokinetics of crizotinib in NSCLC patients.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Is there potential to target FOXM1 for 'undruggable' lung cancers?The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers.Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells.Value: Changes in the Detection and Recognition Thresholds of Three Basic Tastes in Lung Cancer Patients Receiving Cisplatin and Paclitaxel and Its Association with Nutritional and Quality of Life Parameters.Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences.
P2860
Q26769884-B44FC18A-843B-4C37-BBCE-D4585072FE9DQ26786580-83172002-1C9B-410A-9838-82DA92694D3AQ28086768-7279678F-CB40-4C27-B56D-A83BD2A2B880Q28606634-F021A0BF-87EC-481C-A546-D8BA0D97FDFCQ35700740-9E35C03D-F177-4399-81AE-F11337BA534BQ35842446-D3769088-36A4-42DA-901E-2566970EA0F4Q37086009-D2F93734-BAFA-4262-AEBE-C054A80E983FQ37707704-88B37821-0828-476F-BC7D-399F4A16913BQ38366828-E46588FE-83C7-45CF-B0EF-78C7583AA94EQ38584379-A9F77E09-99A6-4F0E-BA56-C2D9E4079CFAQ40332020-35495D14-6D59-40D1-A65D-993279186E1EQ41587809-38E2FDD6-5714-49BA-ADEE-BBAA72D5ACF6Q41825963-559D8E9D-9A3A-43CB-8A36-164BE5C709C6Q46395036-D3DD3B9F-3EE2-435E-B9F7-B96A11FE0007Q47806989-308B70DC-30FA-49E6-8248-3C6BEF74FE8AQ48505836-8DD6442B-86B1-4A05-A311-E2C5B96241F4Q50985108-C42F9D15-B17E-4306-B7E1-3E647ED18EB6
P2860
Novel agents in development for advanced non-small cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Novel agents in development for advanced non-small cell lung cancer.
@ast
Novel agents in development for advanced non-small cell lung cancer.
@en
Novel agents in development for advanced non-small cell lung cancer.
@nl
type
label
Novel agents in development for advanced non-small cell lung cancer.
@ast
Novel agents in development for advanced non-small cell lung cancer.
@en
Novel agents in development for advanced non-small cell lung cancer.
@nl
prefLabel
Novel agents in development for advanced non-small cell lung cancer.
@ast
Novel agents in development for advanced non-small cell lung cancer.
@en
Novel agents in development for advanced non-small cell lung cancer.
@nl
P2860
P356
P1476
Novel agents in development for advanced non-small cell lung cancer.
@en
P2093
Thomas E Stinchcombe
P2860
P304
P356
10.1177/1758834014532510
P577
2014-09-01T00:00:00Z